C2N Diagnostics said that its PrecivityAD2 blood biomarker (BBM) test has improved healthcare providers’ ability to assess Alzheimer’s disease (AD) probability.

The test helped in the detection of amyloid plaques in the brain, a key AD indicator, said C2N Diagnostics.

This enhancement in the clinician-reported probability of AD also led to enhanced downstream clinical care, including adjusted AD medication plans and further brain amyloid testing.

The Quality Improvement PrecivityAD2 (QUIP II) study showed that the PrecivityAD2 blood test significantly boosted clinicians’ diagnostic confidence in AD. For patients with a positive Amyloid Probability Score 2 (APS2) result, confidence rose from 50-60% to over 90%, guiding treatment decisions.

It involved eight academic and community practice sites, with 12 memory specialists treating 203 patients showing AD symptoms or other cognitive decline causes.

The final analysis included 28% of patients from typically under-represented Black, Hispanic, and Asian minorities, with a median age of 74.

In these patients, AD medication prescribing increased by 35%, along with higher use of lecanemab, a disease-modifying therapy.

For patients with a negative APS2 result, AD medication prescribing dropped by over 70%, and additional brain amyloid testing decreased.

Additionally, clinicians adhered closely to the blood test’s intended use criteria in prescribing it, according to the results.

C2N Diagnostics CEO Joel Braunstein said: “Too often, patients face a complex and delayed diagnostic journey when dealing with new cognitive concerns.

“High-performance testing with our PrecivityAD2 blood test has the potential to provide clarity and shorten that diagnostic journey, while significantly elevating healthcare quality.” 

This research adds to a 2024 study, which examined how the PrecivityAD2 blood test’s APS2 result improved Alzheimer’s diagnosis accuracy in primary care settings.

At a pre-defined, single binary cutoff, the APS2 result achieved over 90% diagnostic accuracy, outperforming cerebrospinal fluid (CSF) analysis and amyloid PET imaging.

The QUIP II study reinforces the findings of the original QUIP I study, which evaluated the PrecivityAD blood test with 43 memory care specialists.

In that study, the PrecivityAD test provided clinically informative results in about 85% of cases, helping clinicians confidently rule in or rule out a diagnosis of clinical AD.

Both the PrecivityAD2 and PrecivityAD blood tests are available through healthcare provider orders. They can be accessed in 49 US states.

Last month, the Toronto Memory Program (TMP) became the first clinic in Canada to offer the PrecivityAD2 blood test.